CA1326632C - Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer - Google Patents

Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Info

Publication number: CA1326632C
Authority: CA; Canada
Prior art keywords: particles; galanthamine; alzheimer; disease; treatment
Prior art date: 1988-10-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA 581365

Other languages

English (en)

Inventor

Bonnie Davis

Morris Goodman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-26

Filing date

1988-10-26

Publication date

1994-02-01

1988-10-26 Application filed by Individual filed Critical Individual

1988-10-26 Priority to CA 581365 priority Critical patent/CA1326632C/fr

1994-02-01 Application granted granted Critical

1994-02-01 Publication of CA1326632C publication Critical patent/CA1326632C/fr

2011-02-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims abstract description 12
229960003980 galantamine Drugs 0.000 title claims abstract description 7
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title claims abstract description 5
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title claims abstract description 5
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title claims abstract description 5
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims abstract description 5
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title claims abstract description 5
208000024827 Alzheimer disease Diseases 0.000 title claims description 5
239000013583 drug formulation Substances 0.000 title 1
239000002245 particle Substances 0.000 claims abstract description 10
239000002775 capsule Substances 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims abstract description 7
229940079593 drug Drugs 0.000 claims abstract description 7
238000009472 formulation Methods 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims abstract description 7
239000011248 coating agent Substances 0.000 claims abstract description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 4
238000000576 coating method Methods 0.000 claims abstract 4
238000013268 sustained release Methods 0.000 claims description 6
239000012730 sustained-release form Substances 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
210000001035 gastrointestinal tract Anatomy 0.000 claims 1
239000000463 material Substances 0.000 claims 1
238000004513 sizing Methods 0.000 abstract description 2
239000008187 granular material Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
-1 hydroxypropyl Chemical group 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 581365 1988-10-26 1988-10-26 Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer Expired - Lifetime CA1326632C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 581365 CA1326632C (fr)	1988-10-26	1988-10-26	Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 581365 CA1326632C (fr)	1988-10-26	1988-10-26	Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number	Publication Date
CA1326632C true CA1326632C (fr)	1994-02-01

Family

ID=27167974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 581365 Expired - Lifetime CA1326632C (fr)	1988-10-26	1988-10-26	Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer

Country Status (1)

Country	Link
CA (1)	CA1326632C (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000038686A1 (fr) *	1998-12-24	2000-07-06	Janssen Pharmaceutica N.V.	Composition de galantamine a liberation controlee
EP1133230A4 (fr) *	1998-11-23	2004-05-26	Bonnie M Davis	Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
WO2007121537A1 (fr)	2006-04-26	2007-11-01	Alphapharm Pty Ltd	Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
AU2004242546B2 (en) *	1998-11-23	2008-05-15	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
WO2011064797A2 (fr)	2009-11-26	2011-06-03	Usv Limited	Compositions pharmaceutiques à libération contrôlée de galantamine

1988
- 1988-10-26 CA CA 581365 patent/CA1326632C/fr not_active Expired - Lifetime

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004242546B2 (en) *	1998-11-23	2008-05-15	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
EP1133230A4 (fr) *	1998-11-23	2004-05-26	Bonnie M Davis	Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
US7939522B1 (en)	1998-11-23	2011-05-10	Bonnie M Davis	Dosage formulations for acetylcholinesterase inhibitors
EP2311441A1 (fr) *	1998-11-23	2011-04-20	Bonnie M. Davis	Formulation de dosage d'inhibiteurs de l'acétylcholinestestérase
BG65306B1 (bg) *	1998-12-24	2008-01-31	Janssen Pharmaceutica N.V.	Лекарствена форма с контролирано освобождаване, съдържаща галантамин
WO2000038686A1 (fr) *	1998-12-24	2000-07-06	Janssen Pharmaceutica N.V.	Composition de galantamine a liberation controlee
CN100370990C (zh) *	1998-12-24	2008-02-27	詹森药业有限公司	控释加兰他敏组合物
US7160559B1 (en)	1998-12-24	2007-01-09	Janssen Pharmaceutica N.V.	Controlled release galantamine composition
CZ301658B6 (cs) *	1998-12-24	2010-05-19	Janssen Pharmaceutica N. V.	Prostredky s rízeným uvolnováním galantaminu
HRP20010463B1 (hr) *	1998-12-24	2011-02-28	Janssen Pharmaceutica N.V.	Smjesa s kontroliranim otpuštanjem koja sadrži galantamin
AP1414A (en) *	1998-12-24	2005-06-13	Janssen Pharmaceutica Nv	Controlled release galantamine composition.
AU775914B2 (en) *	1998-12-24	2004-08-19	Janssen Pharmaceutica N.V.	Controlled release galantamine composition
WO2007121537A1 (fr)	2006-04-26	2007-11-01	Alphapharm Pty Ltd	Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
EP2010158B1 (fr)	2006-04-26	2016-02-17	Alphapharm Pty Ltd.	Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
WO2011064797A2 (fr)	2009-11-26	2011-06-03	Usv Limited	Compositions pharmaceutiques à libération contrôlée de galantamine

Legal Events

Date	Code	Title	Description
2011-02-01	MKEX	Expiry	Effective date: 20110201

Publication	Publication Date	Title
KR0140492B1 (ko)	1998-06-01	방출억제성 오피오이드 제형
CA1318600C (fr)	1993-06-01	Etodolac a liberation prolongee
DE3879080T2 (de)	1993-07-15	Pharmazeutische matrix mit verzoegerter freisetzung und verfahren.
US4851226A (en)	1989-07-25	Chewable medicament tablet containing means for taste masking
US5169642A (en)	1992-12-08	Sustained-release drug dosage units
US5122384A (en)	1992-06-16	Oral once-per-day organic nitrate formulation which does not induce tolerance
DE69732113T2 (de)	2005-12-08	Schnelllösliche tablette enthaltend galanthaminhydrobromid
HU199677B (en)	1990-03-28	Process for producing retard pharmaceutical composition
PL172571B1 (pl)	1997-10-31	Doustny preparat morfiny PL PL PL
NZ238131A (en)	1992-09-25	Chewable medicament tablets formed from compressed coated granules; coating is a polymer blend masking taste and providing sustained release
CA1336069C (fr)	1995-06-27	Comprime de medicament contenant un produit masquant le gout
US5268182A (en)	1993-12-07	Sustained-release drug dosage units of terazosin
DE3719818C2 (de)	1997-02-13	Pharmazeutische Zusammensetzung
CZ282679B6 (cs)	1997-08-13	Použití 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazolu pro výrobu farmaceutického prostředku
CY1653A (en)	1993-05-14	Pharmaceutical compositions with analgesic properties and the preparation and use thereof
CA1326632C (fr)	1994-02-01	Compositions pharmaceutiques a action prolongee contenant de la galanthamine pour le traitement de la maladie d'alzheimer
US4968506A (en)	1990-11-06	Pharmaceutical dosage with core of N-acetyl cystein
US5853756A (en)	1998-12-29	Controlled release formulations of Ranitidine
US6251429B1 (en)	2001-06-26	Programmed release ambroxol—HCl dosage forms
WO2005044238A1 (fr)	2005-05-19	Formes posologiques solides a liberation modifiee de sels d'amphetamine
KR20030081027A (ko)	2003-10-17	피복 고형 최면 제제
AU668376B2 (en)	1996-05-02	Antimalarial synergistic compositions containing benflumetol
DE3736866A1 (de)	1989-05-11	Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
CN108309949B (zh)	2020-04-07	一种吗啡渗透泵片的制备方法及其产品
EP0761209A2 (fr)	1997-03-12	Formulations de la ranitidine à libération commandée